15 results about "Interferon alpha" patented technology

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The present invention provides fusion proteins comprising human IFN-[alpha] 2, a first antigen-binding domain capable of binding to human PD-L1, a second antigen-binding domain capable of binding to human PD-L1 and to human IFN-[alpha] 2, and methods of using the same.

The invention relates to the technical field of medicines, and particularly discloses application of interferon alpha combined with stiripentanol in virus infection resistance. As an antiviral drug, interferon alpha has the problems of limited curative effect, remarkable side effect, narrow applicable crowd, inconvenience in medication and the like clinically. The invention finds that the accumulation of host lactic acid in the later stage of virus infection is a key negative factor, and lactic acid directly inhibits the antiviral activity of interferon alpha and induces inflammatory storm. Through combined use of a lactic dehydrogenase inhibitor stiripentol (Stiripentol, STP), lactic acid production is reduced, a lactic acid-mediated antiviral inhibition-inflammation promotion effect is reversed, and the antiviral activity of interferon alpha is enhanced and side effects are reduced. Experiments prove that the combined therapy can effectively inhibit virus replication and inflammatory factor expression, and a new strategy is provided for broad-spectrum antiviral therapy.

Provided herein are methods for treating a brachyury-associated cancer or neoplasm, e.g., chordoma, with a type I interferon in a subject in need thereof. The methods further include treating the brachyury-associated cancer or neoplasm with interferon alpha or interferon beta by injection of interferon protein into a subject in need thereof, wherein the interferon can be an interferon polypeptide or an interferon nucleic acid formulated for expression.

The present disclosure provides a method of treating a cancer in a subject, the method comprising administering to the subject an effective amount of an immunotherapeutic, wherein the subject has been determined to have a T cell signature (TCS) comprising: (a) a composite expression level A comprising the expression of three or more genes selected from Thymocyte Expressed, Positive Selection Associated 1 (TESPA1), Cluster of Differentiation 28 (CD28), G Protein-Coupled Receptor 183 (GPR183), and Zeta-Chain-Associated Protein Kinase 70 (ZAP70) as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2; or (b) a composite expression level B comprising (i) the expression of three or more genes selected from TESPA1, CD28, GPR183 and ZAP70 as measured by log2tpm corresponding to a composite log2tpm value of greater than or equal to 3.2, minus (ii) the expression of Interferon Alpha Inducible Protein 27 (IFI27) gene as measured by log2tpm, wherein the composite expression level B corresponds to a value of greater than or equal to -0.25.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

Provided herein are human interferon alpha-2 (IFNA2) variants that have decreased or no detectable binding to the human interferon-alpha / beta receptor beta 2 (IFNAR2) as compared to the wild-type human IFNA2 polypeptide. Also provided herein are fusion proteins comprising an antibody or fragment thereof, and a human IFNA2 variant, wherein the IFNA2 variant is covalently linked to the antibody, and wherein the IFNA2 variant has decreased or no detectable binding to the human interferon-alpha / beta receptor beta (IFNAR2) as compared to the wild-type human IFNA2 polypeptide.

The application discloses a method for improving the antiviral efficacy of rainbow trout type I interferon alpha protein and belongs to the technical field of medical drugs. The method is that resistant starch and carboxymethyl chitosan are used as microencapsulation materials to perform microencapsulation treatment on the interferon alpha protein. A new combination mode of coating materials, resistant starch-carboxymethyl chitosan, is adopted, wherein the resistant starch has excellent enzyme resistance and colon targeting property, can prolong the half-life of the interferon protein in the body and has a long action time. The carboxymethyl chitosan has excellent water solubility and film forming property. After the two composite materials are used for coating, the highest encapsulation rate can reach 23.09%, the highest drug loading rate can reach 81.20%, and the effect is remarkable. The prepared oral interferon microcapsules by using the method are simple in use, have more obvious antiviral effect and have excellent application prospect, and a new idea is provided for microencapsulation coating.

This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with modified Nle substituted, Gly at position 45 substituted to Asp and / or Asn at position 66 substituted to Lys substituted modified interferon alpha 2 b, and / or a mixture thereof is disclosed herein.

The application discloses application of a probiotic preparation in vaginal flora regulation and anti-HPV, and relates to the technical field of biological medicine; a pharmaceutical composition for assisting in treating high-risk human papilloma virus infection, the pharmaceutical composition comprising: interferon, which is recombinant human interferon alpha-2b; and a vaginal probiotic preparation, which comprises an effective dose of lactobacillus live bacteria; wherein the interferon and the probiotic preparation are formulated into a combined preparation or separate preparations for vaginal administration. The application discloses a new mechanism that the probiotic activates specific immune pathways to synergistically resist viruses, and proves excellent curative effects of the combined therapy; in traditional cognition, the probiotic mainly restores flora balance through occupying competition and acid production.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b with deamidated amino acids is disclosed herein.

The invention belongs to the technical field of protein engineering, and particularly relates to a sheep alpha interferon and sheep interleukin 2 fusion protein and a preparation method thereof. The preparation method comprises the following steps: connecting a ShIFNalpha-IL2 fragment to a pET32a vector to obtain a recombinant plasmid pET32a-ShIFNalpha-IL2; transforming into an E.coli BL21 competent cell, and inducing expression; and centrifuging, collecting the strain, resuspending, carrying out ultrasonic treatment, injecting inclusion body BB, completely draining, injecting the supernatant filtrate, completely draining, injecting inclusion body BB, washing, and eluting the target protein in the column by using inclusion body EB to obtain the ShIFNalpha-IL2 recombinant protein. Through SDS-PAGE electrophoresis detection, separation and purification of the fusion protein of the sheep interferon alpha and the sheep interleukin 2 are realized, and the target protein with relatively high purity is obtained. The fusion protein also has a high expression level, can effectively prolong the retention time of interferon in vivo, and improves the half-life period of interferon.

A composition and a new method of manufacturing and producing such composition including modified interferon alpha 2 b, modified acetylated interferon alpha 2 b, and / or a mixture thereof is disclosed herein.